Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy.

Détails

Ressource 1Télécharger: BIB_3F481AA1AE02.P001.pdf (125.98 [Ko])
Etat: Serval
Version: de l'auteur
ID Serval
serval:BIB_3F481AA1AE02
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy.
Périodique
British Journal of Cancer
Auteur(s)
Franceschi S., Maso L.D., Rickenbach M., Polesel J., Hirschel B., Cavassini M., Bordoni A., Elzi L., Ess S., Jundt G., Mueller N., Clifford G.M.
ISSN
1532-1827 (Electronic)
ISSN-L
0007-0920
Statut éditorial
Publié
Date de publication
2008
Peer-reviewed
Oui
Volume
99
Numéro
5
Pages
800-804
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Résumé
Between 1984 and 2006, 12 959 people with HIV/AIDS (PWHA) in the Swiss HIV Cohort Study contributed a total of 73 412 person-years (py) of follow-up, 35 551 of which derived from PWHA treated with highly active antiretroviral therapy (HAART). Five hundred and ninety-seven incident Kaposi sarcoma (KS) cases were identified of whom 52 were among HAART users. Cox regression was used to estimate hazard ratios (HR) and corresponding 95% confidence intervals (CI). Kaposi sarcoma incidence fell abruptly in 1996-1998 to reach a plateau at 1.4 per 1000 py afterwards. Men having sex with men and birth in Africa or the Middle East were associated with KS in both non-users and users of HAART but the risk pattern by CD4 cell count differed. Only very low CD4 cell count (<50 cells microl(-1)) at enrollment or at HAART initiation were significantly associated with KS among HAART users. The HR for KS declined steeply in the first months after HAART initiation and continued to be low 7-10 years afterwards (HR, 0.06; 95% CI, 0.02-0.17). Thirty-three out of 52 (63.5%) KS cases among HAART users arose among PWHA who had stopped treatment or used HAART for less than 6 months.
Mots-clé
Acquired Immunodeficiency Syndrome/complications, Acquired Immunodeficiency Syndrome/drug therapy, Antiretroviral Therapy, Highly Active, Cohort Studies, Humans, Incidence, Proportional Hazards Models, Sarcoma, Kaposi/complications, Sarcoma, Kaposi/epidemiology, Switzerland
Pubmed
Web of science
Open Access
Oui
Création de la notice
26/02/2009 11:31
Dernière modification de la notice
08/05/2019 17:32
Données d'usage